Literature DB >> 6660320

Interspecies pharmacokinetic scaling and the Dedrick plots.

H Boxenbaum, R Ronfeld.   

Abstract

Interspecies variations in pharmacokinetics are frequently the consequence of organisms living in different time domains. Whereas species' parameter values differ when referenced to chronological time, scaling of data with respect to active mass (ergosomes) and to ideal (mathematical) pharmacokinetic space time (mesochrons, kallynochrons, or apolysichrons) removes the astronomical time dependency. A theory of pharmacokinetic similarities is presented which states that both physiological and pharmacokinetic processes are biologically interrelated and governed by a master synchronization mechanism; consequently interspecies pharmacokinetic events frequently may be expressed as invariant values; e.g., hexobarbital disposition half-life is approximately the duration of 1,680 gut beats (time standard) regardless of mammalian species. The depletion theory hypothesis of aging that each mammalian organism of set mass is genetically endowed with a set total energy or metabolism (lebenszeitliche Kraft) is found to be adaptable at the microscopic pharmacokinetic level; thus it is hypothesized that each mammalian organism has a genetically determined and finite quantity of phase I hepatic pharmacokinetic stuff (activity) to expend during a lifetime and that this pharmacokinetic stuff (ml cleared X kg-1 X maximum life-span potential-1) is a constant. The rate at which this pharmacokinetic stuff is utilized (comparative pharmacokinetics) is presumed to be regulated by a pharmacokinetic clock, which may undergo either acute or chronic perturbations having either a genetic or environmental origin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6660320     DOI: 10.1152/ajpregu.1983.245.6.R768

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  27 in total

1.  A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics.

Authors:  R E Oliver; A F Jones; M Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

Review 2.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

Review 3.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

4.  Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling.

Authors:  V F Cosson; E Fuseau; C Efthymiopoulos; A Bye
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

5.  Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals.

Authors:  J Mordenti
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

6.  Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions. I. Log-convex drug disposition curves.

Authors:  M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1986-12

7.  Allometric scaling of pegylated liposomal anticancer drugs.

Authors:  Whitney P Caron; Harvey Clewell; Robert Dedrick; Ramesh K Ramanathan; Whitney L Davis; Ning Yu; Margaret Tonda; Jan H Schellens; Jos H Beijnen; William C Zamboni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-24       Impact factor: 2.745

8.  Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.

Authors:  An Van den Bergh; Vikash Sinha; Ron Gilissen; Roel Straetemans; Koen Wuyts; Denise Morrison; Luc Bijnens; Claire Mackie
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

9.  Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats.

Authors:  W L Chiou; F H Hsu
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

10.  Projection of exposure and efficacious dose prior to first-in-human studies: how successful have we been?

Authors:  Christine Huang; Ming Zheng; Zheng Yang; A David Rodrigues; Punit Marathe
Journal:  Pharm Res       Date:  2007-09-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.